PE20180506A1 - Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares - Google Patents

Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares

Info

Publication number
PE20180506A1
PE20180506A1 PE2017002482A PE2017002482A PE20180506A1 PE 20180506 A1 PE20180506 A1 PE 20180506A1 PE 2017002482 A PE2017002482 A PE 2017002482A PE 2017002482 A PE2017002482 A PE 2017002482A PE 20180506 A1 PE20180506 A1 PE 20180506A1
Authority
PE
Peru
Prior art keywords
treatment
heteroaryl
apj
ona
pyridin
Prior art date
Application number
PE2017002482A
Other languages
English (en)
Inventor
James A Johnson
Soong-Hoon Kim
R Michael Lawrence
Michael C Myers
Hannguang J Chao
Monique Phillips
Ji Jiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20180506A1 publication Critical patent/PE20180506A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a un compuesto de formula (I), donde A es un anillo tal como 3-etil-1,3,4-oxadiazol, 3-etil-1,2,4-oxadiazol, entre otros; el anillo B puede ser heteroarilo de 6 miembros; R1 es halogeno, NO2, entre otros. Los compuestos preferidos: 3-(5-bencil-1,3,4-oxadiazol-2-il)-6-butil-5-(2,6-dimetoxifenil)piridin-2,4-diol; 3-(5-bencil-1,3,4-oxadiazol-2-il)-6-butil-5-(2,6-dimetoxifenil-4-metilfenil)piridin-2,4-diol, entre otros. Tambien se refiere a una composicion farmaceutica, siendo util en los tratamientos de enfermedades cardiovasculares.
PE2017002482A 2015-06-03 2016-06-02 Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares PE20180506A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562170215P 2015-06-03 2015-06-03

Publications (1)

Publication Number Publication Date
PE20180506A1 true PE20180506A1 (es) 2018-03-09

Family

ID=56131647

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002482A PE20180506A1 (es) 2015-06-03 2016-06-02 Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares

Country Status (35)

Country Link
US (3) US10011594B2 (es)
EP (2) EP3303330B1 (es)
JP (2) JP6483288B2 (es)
KR (1) KR102066336B1 (es)
CN (1) CN107922401B (es)
AR (1) AR104884A1 (es)
AU (1) AU2016270903B2 (es)
CA (1) CA2988147C (es)
CL (1) CL2017003055A1 (es)
CO (1) CO2017013229A2 (es)
CY (1) CY1121938T1 (es)
DK (1) DK3303330T3 (es)
EA (1) EA034912B1 (es)
ES (1) ES2739526T3 (es)
HK (1) HK1247915B (es)
HR (1) HRP20191327T1 (es)
HU (1) HUE045546T2 (es)
IL (1) IL255951B (es)
LT (1) LT3303330T (es)
MA (1) MA41562B1 (es)
ME (1) ME03474B (es)
MX (1) MX2017014956A (es)
MY (1) MY189453A (es)
NZ (1) NZ738563A (es)
PE (1) PE20180506A1 (es)
PH (1) PH12017502158A1 (es)
PL (1) PL3303330T3 (es)
PT (1) PT3303330T (es)
RS (1) RS59220B1 (es)
SI (1) SI3303330T1 (es)
TN (1) TN2017000503A1 (es)
TW (1) TWI672299B (es)
UY (1) UY36705A (es)
WO (1) WO2016196771A1 (es)
ZA (1) ZA201708191B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
CN108368087B (zh) 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
US11390616B2 (en) 2015-12-04 2022-07-19 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
JP6948322B2 (ja) * 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
EP3433247B1 (en) 2016-03-24 2021-09-08 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2017218617A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
EP3468956B1 (en) 2016-06-14 2021-03-03 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists
EP3526198B1 (en) * 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
CN109734616B (zh) * 2019-02-16 2022-05-13 安徽诺全药业有限公司 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN109704981B (zh) * 2019-02-16 2022-01-28 安徽诺全药业有限公司 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001159A (en) 1910-07-25 1911-08-22 Elizabeth Nielsen Skirt-gage.
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US4866182A (en) 1988-02-18 1989-09-12 Merrell Dow Pharmaceuticals Inc. Cardiotonic alkanoyl and aroyl oxazolones
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
BR0207390A (pt) 2001-02-21 2004-10-13 Nps Pharma Inc Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur
WO2002079143A1 (en) 2001-03-28 2002-10-10 Pfizer Limited N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad
WO2003020719A1 (fr) 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. Derives de 1,3-benzothiazinone et leur utilisation
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
US7067540B2 (en) * 2002-02-14 2006-06-27 Pharmacia Corporation Substituted pyridinones
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
PT1735278E (pt) 2004-04-01 2010-03-09 Lilly Co Eli Agentes receptores h3 de histamina, sua preparação e utilizações terapêuticas
EP1893572B1 (en) 2004-06-18 2016-12-14 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
BRPI0513777A (pt) 2004-07-26 2008-05-13 Lilly Co Eli composto ou um sal do mesmo, composição farmacêutica, e, uso de um composto ou de um sal do mesmo
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
JP2008540626A (ja) * 2005-05-19 2008-11-20 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007023242A1 (en) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
JP5280862B2 (ja) 2006-01-23 2013-09-04 アムジエン・インコーポレーテツド オーロラキナーゼ調節剤および使用方法
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd ２以上の置換基を有するベンゼン化合物を含有する医薬
AU2007281212B8 (en) 2006-08-03 2013-02-28 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
EP2099768A2 (en) 2006-08-04 2009-09-16 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1-phosphate receptor
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP2089026A2 (en) 2006-12-01 2009-08-19 Novartis AG Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy
EP2132208A1 (en) 2007-03-28 2009-12-16 NeuroSearch AS Purinyl derivatives and their use as potassium channel modulators
JP2011504505A (ja) * 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
JP2011510067A (ja) 2008-01-25 2011-03-31 トレント・ファーマシューティカルズ・リミテッド 組合せ医薬品
PE20091838A1 (es) 2008-04-09 2009-12-18 Infinity Pharmaceuticals Inc Inhibidores de amida hidrolasa de acido graso
RU2010154473A (ru) 2008-05-30 2012-07-10 Фостер Вилер Энергия Ой (Fi) Способ и устройство для генерации мощности сжиганием обогащенного кислородом топлива
WO2010002933A1 (en) 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
US8501804B2 (en) 2008-10-27 2013-08-06 Takeda Pharmaceutical Company Limited Bicyclic compound
JP2012507523A (ja) * 2008-11-04 2012-03-29 アンカー セラピューティクス，インコーポレイテッド Ａｐｊ受容体化合物
BR112012006628A2 (pt) 2009-09-24 2016-05-03 Hoffmann La Roche compostos antivírus heterocíclos
CA2771026A1 (en) 2009-09-24 2011-03-31 F. Hoffmann-La Roche Ag Indole derivatives as crac modulators
US8609663B2 (en) 2009-11-18 2013-12-17 University Of Massachusetts Compounds for modulating TLR2
EP2512466A4 (en) 2009-12-18 2013-07-03 Activesite Pharmaceuticals Inc PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
US9096531B2 (en) 2010-05-24 2015-08-04 Toa Eiyo Ltd. Fused imidazole derivative
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012074022A1 (ja) 2010-12-01 2012-06-07 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
JP2014514257A (ja) 2011-03-03 2014-06-19 ユニバーシテーテ デス ザールランデス 選択的１７ベータ−ヒドロキシステロイドデヒドロゲナーゼ２型阻害剤としてのビアリール誘導体
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
EP2794601B1 (en) 2011-12-23 2019-02-20 Basf Se Isothiazoline compounds for combating invertebrate pests
EP2844655A1 (en) * 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
AU2013272288B2 (en) 2012-06-08 2018-01-18 The United States Government As Represented By The Department Of Veterans Affairs FBXO3 inhibitors
EP2866803A1 (en) 2012-07-02 2015-05-06 Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
EP2888256A4 (en) 2012-08-24 2016-02-17 Univ Texas HETEROCYCLIC HIF ACTIVITY MODULATORS FOR THE TREATMENT OF DISEASES
PL2897939T3 (pl) * 2012-09-21 2017-08-31 Sanofi Pochodne amidu kwasu benzoimidazolo-karboksylowego do leczenia chorób metabolicznych i sercowo-naczyniowych
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
JP6199197B2 (ja) 2014-02-07 2017-09-20 花王株式会社 ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法
JP2017071553A (ja) 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
WO2015140195A1 (en) 2014-03-20 2015-09-24 Bayer Pharma Aktiengesellschaft Novel compounds
US9969726B2 (en) 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
HUE050317T2 (hu) 2015-05-20 2020-11-30 Amgen Inc APJ receptor triazol agonistái
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
CN108368087B (zh) 2015-10-14 2022-04-12 百时美施贵宝公司 作为apj激动剂的2，4-二羟基-烟酰胺
US10626096B2 (en) 2015-11-24 2020-04-21 Sanford Burnham Prebys Medical Discovery Institute Azole derivatives as apelin receptor agonist
US11390616B2 (en) 2015-12-04 2022-07-19 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
RU2021133849A (ru) 2015-12-09 2022-03-21 Рисерч Трайэнгл Инститьют Улучшенные агонисты апелинового рецептора (apj) и их использование
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
EP3433247B1 (en) 2016-03-24 2021-09-08 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
WO2017218617A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
EP3468956B1 (en) 2016-06-14 2021-03-03 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-ones as apj agonists
EP3526198B1 (en) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists

Also Published As

Publication number Publication date
AU2016270903B2 (en) 2020-04-30
BR112017024846A2 (pt) 2018-08-07
MY189453A (en) 2022-02-14
EA201792548A1 (ru) 2018-06-29
KR102066336B1 (ko) 2020-01-14
PT3303330T (pt) 2019-08-05
AR104884A1 (es) 2017-08-23
US20180273518A1 (en) 2018-09-27
EA034912B1 (ru) 2020-04-06
IL255951A (en) 2018-01-31
ES2739526T3 (es) 2020-01-31
CA2988147A1 (en) 2016-12-08
PH12017502158A1 (en) 2018-06-11
JP2018516928A (ja) 2018-06-28
JP2019094345A (ja) 2019-06-20
HK1247915B (zh) 2020-04-24
PL3303330T3 (pl) 2019-10-31
SI3303330T1 (sl) 2019-08-30
US10336739B2 (en) 2019-07-02
ME03474B (me) 2020-01-20
EP3530660A1 (en) 2019-08-28
AU2016270903A1 (en) 2018-01-18
TW201708214A (zh) 2017-03-01
MA41562A1 (fr) 2018-05-31
EP3303330A1 (en) 2018-04-11
US20190263791A1 (en) 2019-08-29
EP3303330B1 (en) 2019-05-01
DK3303330T3 (da) 2019-08-05
KR20180014422A (ko) 2018-02-08
JP6483288B2 (ja) 2019-03-13
US10011594B2 (en) 2018-07-03
HRP20191327T1 (hr) 2019-11-01
CO2017013229A2 (es) 2018-03-28
MA41562B1 (fr) 2019-05-31
WO2016196771A1 (en) 2016-12-08
LT3303330T (lt) 2019-08-12
CA2988147C (en) 2023-06-13
CY1121938T1 (el) 2020-10-14
US20160355507A1 (en) 2016-12-08
TN2017000503A1 (en) 2019-04-12
ZA201708191B (en) 2019-07-31
IL255951B (en) 2021-06-30
NZ738563A (en) 2019-09-27
CL2017003055A1 (es) 2018-05-25
MX2017014956A (es) 2018-04-13
HUE045546T2 (hu) 2020-01-28
RS59220B1 (sr) 2019-10-31
UY36705A (es) 2016-11-30
CN107922401A (zh) 2018-04-17
CN107922401B (zh) 2021-04-16
TWI672299B (zh) 2019-09-21

Similar Documents

Publication Publication Date Title
PE20180506A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
CU20170087A7 (es) Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
ECSP20070854A (es) Compuestos heteroaril tetracíclicos
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
PE20190329A1 (es) Compuestos moduladores de fxr (nr1h4)
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CL2017000271A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20190710A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20161368A1 (es) Inhibidores de diacilglicerol aciltranferasa 2
PE20181197A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
PE20141996A1 (es) Compuestos con actividad nematicida
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
CL2019002893A1 (es) Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos.
CL2020002588A1 (es) Compuestos derivados de indol, composiciones que los contienen, útiles en el tratamiento de infestación por helmintos, preferentemente trematodos, en mamíferos. (divisional de solicitud n° 03258-2016)
PE20161407A1 (es) Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
ECSP19062381A (es) Moduladores del receptor de estrógeno
AR067057A1 (es) Oxazolidinonas sustituidas y su uso
CU20160148A7 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2
PE20151884A1 (es) Formas cristalinas de inhibidores de tirosina cinasa y sus sales
CR20160016A (es) Pirazolpiridinas sustituidas